Microbiota in intensive care: no demonstrated reduction in mortality with the interventions studied

Could modifying the gut microbiota prevent infections in intensive care? A meta-analysis of randomized trials in adults finds encouraging results for certain infections, particularly pneumonia. But neither supplementation with prebiotics, probiotics or synbiotics nor digestive decontamination with antibiotics significantly reduced overall mortality in this analysis.

Illustration of the gut microbiota and the two strategies studied to prevent infections in intensive care.
SupplementsEditorial illustration, not study data.

Two opposing approaches, with no direct comparison

In intensive care, gut colonization by potentially pathogenic microbes is common and often precedes a clinical infection. The interventions studied aim to target this reservoir in two ways: eliminating certain microbes with antibiotics, or promoting beneficial microbes with prebiotics, probiotics or synbiotics.

The researchers searched PubMed for randomized trials published between 2000 and 2025 involving adults in intensive care. Their review includes nine trials of selective digestive decontamination, totaling 19,907 participants, and 29 supplementation trials involving 5,483 participants.

Each approach was compared with usual care or a placebo. No trial directly compared the two strategies, so considering their results together cannot establish which would be superior.

A signal for infections, not survival

For overall mortality, the relative risk with digestive decontamination was 0.96, with a 95% confidence interval of 0.88 to 1.05. For supplementation, it was 0.93, with an interval of 0.87 to 1.00. The authors report no statistically significant reduction for either approach. This does not demonstrate a complete absence of effect, but it does not establish a survival benefit.

For all infections acquired in intensive care, the relative risk was 0.76 with digestive decontamination, versus 0.82 with supplementation, each compared with its own control group. Only the first result was statistically significant. The difference between the strategies was not.

For pneumonia, the analysis reports a relative risk of 0.50 for digestive decontamination and 0.70 for prebiotics and synbiotics. This latter result should not be attributed indiscriminately to all probiotics. The abstract does not provide absolute risks, which are needed to translate these results into numbers of infections prevented.

Not a reason to take a supplement

The studies were heterogeneous, particularly those examining supplementation. Based on the available abstract, pooling them does not identify a preferred product or intervention.

These results concern adults hospitalized in intensive care. They do not demonstrate that a supplement intended for the general public prevents infections in a healthy person. Nor are they sufficient to turn a signal for pneumonia into a recommendation for supplementation.

Limitations to keep in mind

Only the PubMed abstract was consulted, not the full text. The studies are heterogeneous, and comparisons between strategies are indirect. The abstract does not detail durations, absolute risks, adverse effects or the assessment of bias. Funding and conflicts of interest were not verified.

What we can take away

This review suggests that certain interventions targeting the microbiota may help prevent infections in intensive care, without a demonstrated mortality benefit. It allows neither a direct comparison of the strategies nor a recommendation of supplements for the general public.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.